Literature DB >> 28369376

Association of circulating tumour cells with early relapse and 18F-fluorodeoxyglucose positron emission tomography uptake in resected non-small-cell lung cancers.

Clara I Bayarri-Lara1, Diego de Miguel Pérez2,3, Antonio Cueto Ladrón de Guevara1, Antonio Rodriguez Fernández4, Jose L Puche2,5, Abel Sánchez-Palencia Ramos1, Javier Ruiz Zafra1, Carlos F Giraldo Ospina1, Miguel Delgado-Rodríguez6, Manuela Expósito Ruiz7, Maria José Moyano Rodriguez1, Jose A Lorente2,3, Maria José Serrano2,6.   

Abstract

OBJECTIVES: More than 20% of lung cancer patients develop a recurrence, even after curative resection. We hypothesized that relapse may arise from the dissemination of circulating tumour cells (CTCs). This study evaluates the significance of CTC detection as regards the recurrence of non-small-cell lung cancer (NSCLC) in surgically resected patients. Secondly, we investigated the association between CTCs and the uptake of 18 F-fluorodeoxyglucose (FDG) by the primary tumour on a positron emission tomographic (PET) scan.
METHODS: In this single-centre prospective study, blood samples for analysis of CTCs were obtained from 102 patients with Stage I-IIIA NSCLC both before (CTC1) and 1 month after (CTC2) radical resection. CTCs were isolated using immunomagnetic techniques. The presence of CTCs was correlated with the maximum standardized uptake value (SUVmax) measured on preoperative FDG PET/computed tomographic scans. Recurrence free survival (RFS) analysis was performed.
RESULTS: CTCs were detected in 39.2% of patients before and in 27.5% 1 month after the operation. The presence of CTCs after the operation was significantly correlated with SUVmax on PET scans, pathological stage and surgical approach. Only SUVmax was an independent predictor for the presence of CTC2 on multivariate analysis. Postoperative CTCs were significantly correlated with a shorter RFS ( P  = 0.005). In multivariate analysis, the presence of CTC2 was associated with RFS, independent of disease staging.
CONCLUSIONS: Detection of CTCs 1 month after radical resection might be a useful marker to predict early recurrence in Stage I-III NSCLC. The SUVmax value of the primary tumour on preoperative PET scans was associated with the presence of CTC 1 month after the operation.
© The Author 2017. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Circulating tumour cells; FDG PET/CT; Non-small-cell lung cancer; Recurrence

Mesh:

Substances:

Year:  2017        PMID: 28369376     DOI: 10.1093/ejcts/ezx049

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  5 in total

1.  18F-FDG PET/CT and circulating tumor cells in treatment-naive patients with non-small-cell lung cancer.

Authors:  Fengxian Zhang; Xiaodong Wu; Junjie Zhu; Yan Huang; Xiao Song; Lei Jiang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-02-25       Impact factor: 9.236

2.  18F-FDG PET/CT total lesion glycolysis is associated with circulating tumor cell counts in patients with stage I to IIIA non-small cell lung cancer.

Authors:  Diego M Avella; Yariswamy Manjunath; Amolak Singh; Chelsea B Deroche; Eric T Kimchi; Kevin F Staveley-O'Carroll; Jonathan B Mitchem; Eric Kwon; Guangfu Li; Jussuf T Kaifi
Journal:  Transl Lung Cancer Res       Date:  2020-06

3.  Post-Surgery Circulating Tumor Cells and AXL Overexpression as New Poor Prognostic Biomarkers in Resected Lung Adenocarcinoma.

Authors:  Diego de Miguel-Pérez; Clara Isabel Bayarri-Lara; Francisco Gabriel Ortega; Alessandro Russo; María José Moyano Rodriguez; Maria Jesus Alvarez-Cubero; Elizabeth Maza Serrano; José Antonio Lorente; Christian Rolfo; María José Serrano
Journal:  Cancers (Basel)       Date:  2019-11-07       Impact factor: 6.639

Review 4.  Liquid biopsy in NSCLC: a new challenge in radiation therapy.

Authors:  Annarita Perillo; Mohamed Vincenzo Agbaje Olufemi; Jacopo De Robbio; Rossella Margherita Mancuso; Anna Roscigno; Maddalena Tirozzi; Ida Rosalia Scognamiglio
Journal:  Explor Target Antitumor Ther       Date:  2021-04-30

Review 5.  Imaging Biomarkers of Tumour Proliferation and Invasion for Personalised Lung Cancer Therapy.

Authors:  Loredana G Marcu
Journal:  J Pers Med       Date:  2020-11-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.